Immunostimulants drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
O’Donnell NCT04359810		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	150/73	inconclusive	inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
Gharebaghi IRCT20200501047259N1		RCT	immunoglobulin therapy	placebo	COVID-19 severe or critically	NA	30/29	suggested	suggested 100 % decrease in deaths,death D28
ILBS-COVID-02 (Bajpai M) NCT04346446		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	high	14/15	inconclusive	inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
PlasmAr NCT04344535		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	228/106	inconclusive	inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis